Evaluation of the protective effect of a prime-boost strategy with plasmid DNA followed by recombinant adenovirus expressing BmAMA1 as vaccines against Babesia microti infection in hamster

In the present study, we have investigated the protective effect of a heterologous prime-boost strategy with priming plasmid DNA followed by recombinant adenovirus, both expressing BmAMA1, against Babesia microti infection. Four groups consisting of 3 hamsters per group were immunized with pBmAMA1/Ad5BmAMA1, pNull/Ad5BmAMA1, pBmAMA1/Ad5Null and pNull/Ad5Null, followed by challenge infection with B. microti. Our results showed that hamsters immunized with plasmid and adenovirus expressing BmAMA1 developed a robust IgG and IgG2a antibody response against BmAMA1, suggesting the DNA vaccine or viral vector vaccine tend to induce a Th1-biased response. Compared to the control hamsters, the hamsters vaccinated either with the prime-boost strategy or one of the two “vaccines” exhibited no significant protection against B. microti challenge. Although a slight difference in terms of parasitemia and hematocrit values at days 14–16 post challenge infection was observed, no other statistical difference was detected. Our results indicate that the prime-boost vaccination strategy of injection of plasmid and adenovirus expressing BmAMA1 is not efficient in protecting against B. microti infection.

[1]  L. Aravind,et al.  Expression, Purification, and Biological Characterization of Babesia microti Apical Membrane Antigen 1 , 2015, Infection and Immunity.

[2]  A. Cowman,et al.  Insights and controversies into the role of the key apicomplexan invasion ligand, Apical Membrane Antigen 1. , 2014, International journal for parasitology.

[3]  D. Barto,et al.  Babesiosis , 2014 .

[4]  K. Fujisaki,et al.  Protective effect of a prime-boost strategy with plasmid DNA followed by recombinant adenovirus expressing TgAMA1 as vaccines against Toxoplasma gondii infection in mice. , 2012, Parasitology international.

[5]  Hiroshi Suzuki,et al.  Construction of Neospora caninum stably expressing TgSAG1 and evaluation of its protective effects against Toxoplasma gondii infection in mice. , 2010, Vaccine.

[6]  J. Barnwell,et al.  High Antibody Titer against Apical Membrane Antigen-1 Is Required to Protect against Malaria in the Aotus Model , 2009, PloS one.

[7]  H. Nakhasi,et al.  CONFERENCE REPORT: Transfusion‐transmitted babesiosis in the United States: summary of a workshop , 2009, Transfusion.

[8]  M. Young,et al.  Persistent and relapsing babesiosis in immunocompromised patients. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  Richard J. Anderson,et al.  Plasmid DNA and viral vector-based vaccines for the treatment of cancer. , 2007, Vaccine.

[10]  M. Kiehntopf,et al.  First confirmed autochthonous case of human Babesia microti infection in Europe , 2007, European Journal of Clinical Microbiology & Infectious Diseases.

[11]  J. Harty,et al.  Viral vector vaccines make memory T cells against malaria , 2007, Immunology.

[12]  P. Morris,et al.  Molecular characterisation of pneumococcal serotype 16F: Established predominant carriage and otitis media serotype in the 7vPCV era. , 2007, Vaccine.

[13]  R. Gazzinelli,et al.  Vaccination with replication-deficient recombinant adenoviruses encoding the main surface antigens of toxoplasma gondii induces immune response and protection against infection in mice. , 2006, Human gene therapy.

[14]  M. Esteban,et al.  MVA-LACK as a safe and efficient vector for vaccination against leishmaniasis. , 2006, Microbes and infection.

[15]  A. Marathe,et al.  Human babesiosis--a case report. , 2005, Indian journal of medical microbiology.

[16]  A. Campos-Neto What about Th1/Th2 in cutaneous leishmaniasis vaccine discovery? , 2005, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[17]  David L Woodland,et al.  Jump-starting the immune system: prime-boosting comes of age. , 2004, Trends in immunology.

[18]  A. Hill,et al.  Prime-boost strategies for malaria vaccine development , 2003, Journal of Experimental Biology.

[19]  Y. Nagai,et al.  Protective Efficacy of an AIDS Vaccine, a Single DNA Priming Followed by a Single Booster with a Recombinant Replication-Defective Sendai Virus Vector, in a Macaque AIDS Model , 2003, Journal of Virology.

[20]  B. Keegan,et al.  Vaccination of Monkeys with Recombinant Plasmodium falciparum Apical Membrane Antigen 1 Confers Protection against Blood-Stage Malaria , 2002, Infection and Immunity.

[21]  A. Ramsay,et al.  The prime-boost strategy: exciting prospects for improved vaccination. , 2000, Immunology today.

[22]  A. Saito,et al.  Roles of CD4+ T Cells and Gamma Interferon in Protective Immunity against Babesia microtiInfection in Mice , 1999, Infection and Immunity.

[23]  R. Wilson,et al.  The profile of IgG1 and IgG2a antibody responses in mice exposed to Schistosoma mansoni , 1994, Parasite immunology.

[24]  C. V. von Essen The Treatment of Cancer , 1966, Nature.

[25]  Hiroshi Suzuki,et al.  Expression of truncated Babesia microti apical membrane protein 1 and rhoptry neck protein 2 and evaluation of their protective efficacy. , 2017, Experimental parasitology.

[26]  J. Ulmer,et al.  Human clinical trials of plasmid DNA vaccines. , 2005, Advances in genetics.

[27]  B. Wahrén Gene vaccines. , 1996, Immunotechnology : an international journal of immunological engineering.

[28]  F. Cox Human babesiosis , 1980, Nature.